What is Techcyte?
Techcyte operates at the intersection of artificial intelligence and digital pathology, providing sophisticated software platforms designed to automate the analysis of medical samples. The company's technology suite supports a diverse array of testing environments, including clinical, veterinary, and environmental laboratories. By integrating advanced machine learning algorithms into the diagnostic process, Techcyte enables laboratories to process blood, tissue, and cytology slides with greater precision and speed. This automation not only reduces the burden on pathologists but also significantly improves diagnostic accuracy, positioning the firm as a critical infrastructure provider in the modern medical landscape.
How much funding has Techcyte raised?
Techcyte has raised a total of $40.5M across 4 funding rounds:
Private Equity
$4.3M
Debt
$150K
Unspecified
$21M
Unspecified
$15M
Private Equity (2018): $4.3M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Unspecified (2021): $21M supported by ARUP Laboratories and Zoetis
Unspecified (2026): $15M featuring Van Tuyl Companies
Key Investors in Techcyte
ARUP Laboratories
ARUP Laboratories is a national reference laboratory and a nonprofit enterprise of the University of Utah, specializing in complex diagnostic testing and pathology services.
Zoetis
Zoetis is a global leader in animal health, focusing on the discovery, development, and commercialization of vaccines and diagnostic products for both livestock and companion animals.
Van Tuyl Companies
Van Tuyl Companies is a diversified investment firm with a strong focus on automotive services and community-oriented philanthropic initiatives.
What's next for Techcyte?
With the recent influx of capital, Techcyte is well-positioned to scale its operations and expand its footprint in the global diagnostics market. The company is expected to prioritize the enhancement of its AI-driven diagnostic models, potentially broadening its application to new medical specialties and testing modalities. As the demand for automated, high-throughput laboratory solutions continues to rise, Techcyte's strategic focus will likely shift toward deepening its integration with existing hospital information systems and expanding its commercial reach. This phase of development will be crucial for maintaining its competitive edge in the rapidly evolving digital pathology sector.
See full Techcyte company page
